OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $16.8750.

A number of equities research analysts recently commented on the stock. Citizens Jmp lifted their price target on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday. UBS Group set a $23.00 price target on OptimizeRx in a research report on Friday, October 10th. Stephens cut their price target on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday.

Insider Activity

In related news, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total transaction of $30,375.00. Following the sale, the chief executive officer directly owned 188,916 shares in the company, valued at approximately $3,542,175. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently bought and sold shares of OPRX. American Century Companies Inc. grew its holdings in shares of OptimizeRx by 9.6% during the 1st quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock valued at $137,000 after purchasing an additional 1,387 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after purchasing an additional 2,188 shares during the last quarter. BNP Paribas Financial Markets boosted its position in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after buying an additional 2,636 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Trading Up 3.7%

NASDAQ OPRX opened at $13.60 on Friday. The business’s fifty day moving average is $16.65 and its 200-day moving average is $15.94. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05. The stock has a market capitalization of $253.52 million, a price-to-earnings ratio of 31.92 and a beta of 1.10. OptimizeRx has a one year low of $3.99 and a one year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The business had revenue of $26.07 million during the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. Equities research analysts predict that OptimizeRx will post -0.33 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.